Abstract
An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.
Keywords:
HIV-1; antibodies; immunogen; neutralization; vaccine.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
AIDS Vaccines / administration & dosage
-
AIDS Vaccines / immunology*
-
Animals
-
Antibodies, Neutralizing / blood
-
Antibodies, Neutralizing / immunology
-
Clinical Trials as Topic
-
Drug Evaluation, Preclinical
-
HIV Antibodies / blood
-
HIV Antibodies / immunology
-
HIV Infections / prevention & control*
-
HIV Infections / therapy*
-
HIV Infections / transmission
-
HIV-1 / genetics
-
HIV-1 / immunology*
-
Host-Pathogen Interactions / immunology
-
Humans
-
Immunogenicity, Vaccine
-
Outcome Assessment, Health Care
-
Structure-Activity Relationship
-
Vaccination
-
Viral Proteins / chemistry
-
Viral Proteins / genetics
-
Viral Proteins / immunology
Substances
-
AIDS Vaccines
-
Antibodies, Neutralizing
-
HIV Antibodies
-
Viral Proteins